Fistula-related morbidity decreased by prompt treatment in Sierra Leone

April 26, 2009

LINTHICUM, MD, April 26, 2009-Extent of fibrosis is the most profound factor in predicting surgical outcomes of genitourinary fistula repair, suggesting that prompt treatment could significantly improve survival. Researchers in Nashville review experiences at two centers in Sierra Leone to assess factors predictive of successful fistula repair. Their findings were presented at the 104th Annual Scientific Meeting of the American Urological Association.

Genitourinary fistulas (abnormal connections between organs or vessels that are normally unconnected) result from prolonged obstructed labor and delivery and are a cause of considerable morbidity in sub-Saharan African countries, such as Sierra Leone. Researchers studied 505 operative repairs from 2004 through 2006. Primary repairs (the patient's first repair) accounted for 68 percent of the procedures, with 92 percent of those being vesicovaginal fistula alone. Only 56 percent of the women were deemed to have an intact bladder neck or urethra at presentation and 68 percent were diagnosed with moderate to severe fibrosis around the fistula. The average patient age at the time of repair was 29.4 years. The average fistula duration, or time before seeking treatment, was 62 months. Conclusions were derived from statistical analysis of demographics, fistula characteristics, outcomes and surgical complications. On multivariate analysis, the only parameter that correlated with successful repair of the fistula was the extent of fibrosis. Researchers also reported that women with previous pregnancies showed significantly improved outcomes compared to first-time mothers.

"This study highlights a major problem in sub-Saharan African countries that is not well known by the general public or much of the medical community in this country. The fistulas these women experience are often much more complex than what we see in our medical communities. Extent of the fibrosis appears to be a barrier to successful repair," said Anthony Y. Smith, MD, an AUA spokesman. "Unfortunately, it can be difficult for women in sub-Saharan Africa to obtain timely care. The broader story of these women and the suffering they endure as well as the courage of the unique physicians who care for them is a story that deserves to be told."
NOTE TO REPORTERS: Experts are available to discuss this study outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at the number above or e-mail Lacey Dean at

Lewis, A; Kaufman, M; Wolter, C; Phillips, S; Maggi, D; Condry, L; Dmochowski, R; Smith, J. Genitourinary fistula experience in Sierra Leone: review of 505 cases. J Urol, suppl. 2009: 181, 4, abstract 1570.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.

American Urological Association

Related Fibrosis Articles from Brightsurf:

One step for fibrosis, one giant leap for scleroderma
At the Medical University of South Carolina, a team of researchers has demonstrated a ''moonlighting'' role for lysyl oxidase (LOX) in scleroderma.

Cystic fibrosis: why so many respiratory complications?
Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders.

Closing in on liver fibrosis: Detailing the fibrosis process at unprecedented resolution
Today, there is no effective way to treat liver fibrosis.

Liver fibrosis 'off switch' discovered in mice
UC San Diego School of Medicine researchers identified several genetic switches, or transcription factors, that determine whether or not liver cells produce collagen -- providing a new therapeutic target for liver fibrosis.

Magnetic nanomaterials become an effective treatment against liver fibrosis
Fibrosis may affect different body organs. It develops as a reaction to long-time inflammation and is supposed to isolate the inflammation site from surrounding tissues.

Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

Short or long sleep associated with Pulmonary Fibrosis
Scientists have discovered that people who regularly sleep for more than 11 hours or less than 4 hours are 2-3 times more likely to have the incurable disease, pulmonary fibrosis, compared to those that sleep for 7 hours in a day.

Promising steps towards a treatment for pulmonary fibrosis
Research published in the journal Science Translational Medicine on 25 September by members of the Cardiovascular Disease Mechanisms group at the MRC LMS in collaboration with Duke-NUS Medical School, National Heart Centre Singapore & National Heart and Lung Institute, Imperial College London, showed that blocking a protein called interleukin-11 (IL-11) using therapeutic antibodies can reverse the fibrosis in the lung.

Cibio knocks out cystic fibrosis
The fight against cystic fibrosis continues, targeting in particular some of the mutations that cause it.

How fibrosis develops in butterfly syndrome patients
Researchers have pinpointed how fibrosis develops in butterfly syndrome patients.

Read More: Fibrosis News and Fibrosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to